On March 23, 2026, Aardvark Therapeutics, Inc. announced that it has entered into an Equity Distribution Agreement with Piper Sandler & Co. as the sales agent. This agreement allows Aardvark to offer and sell shares of its common stock, with an aggregate offering price of up to $150 million. The shares will be sold under the company's shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission on the same date. The company will pay Piper Sandler a commission of 3.0% on the gross sales price of the shares sold under this agreement. Aardvark has no obligation to sell any shares under this agreement, and it has agreed to indemnify the agent against certain liabilities, including those under the Securities Act of 1933. This move is seen as a strategic step to enhance liquidity and provide the company with additional capital for its operations and growth initiatives. The company is classified as an emerging growth company, which may allow it to take advantage of certain regulatory benefits. The agreement is expected to have a positive impact on Aardvark's financial flexibility, although the actual effect on stock price will depend on market conditions and investor sentiment.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.